Article
Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
The New England journal of medicine - 29 Mar 2018
Jongen-Lavrencic Mojca, Grob Tim, Hanekamp Diana, Kavelaars François G, Al Hinai Adil, Zeilemaker Annelieke, Erpelinck-Verschueren Claudia A J, Gradowska Patrycja L, Meijer Rosa, Cloos Jacqueline, Biemond Bart J, Graux Carlos, van Marwijk Kooy Marinus, Manz Markus G, Pabst Thomas, Passweg Jakob R, Havelange Violaine, Ossenkoppele Gert J, Sanders Mathijs A, Schuurhuis Gerrit J, Löwenberg Bob, Valk Peter J M
Abstract excerpt
BACKGROUND: Patients with acute myeloid leukemia (AML) often reach complete remission, but relapse rates remain high. Next-generation sequencing enables the detection of molecular minimal residual disease in virtually every patient, but its clinical value for the prediction of relapse has yet to be established. METHODS: We conducted a study involving patients 18 to 65 years of age who had newly diagnosed AML....
Topics
Join the communities discussing this publication.